[1] It also acts as a vasodilator[2] and induces apoptosis in some cancer cell lines.

[5][6] 2-Methoxyestradiol was being developed as an experimental drug candidate with the tentative brand name Panzem.

[8] A phase II trial of 18 advanced ovarian cancer patients reported encouraging results in October 2007.

[9] Preclinical models also suggest that 2-methoxyestradiol could also be effective against inflammatory diseases such as rheumatoid arthritis.

Several studies have been conducted showing 2-methoxyestradiol is a microtubule inhibitor[10] and is inhibitory against prostate cancer in rodents.